

Pedro Aguiar JÃºnior

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8162345/publications.pdf>

Version: 2024-02-01

50
papers

634
citations

933447

10
h-index

580821

25
g-index

51
all docs

51
docs citations

51
times ranked

1509
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Predictive genetic biomarkers in immune checkpoint inhibitors for non-small-cell lung cancer.. Immunotherapy, 2022, , . | 2.0 | 0 |
| 2 | Cost-effectiveness analysis of Ado-trastuzumab emtansine for the treatment of residual invasive HER2-positive breast cancer. Einstein (Sao Paulo, Brazil), 2022, 20, eGS6655. | 0.7 | 1 |
| 3 | Laboratory variables as predictors of progression in gastroenteropancreatic neuroendocrine tumors in different lines of antineoplastic treatments. Einstein (Sao Paulo, Brazil), 2022, 20, . | 0.7 | 0 |
| 4 | Patient-centered outcomes in non-small-cell lung cancer: a real-world perspective. Future Oncology, 2021, 17, 1721-1733. | 2.4 | 3 |
| 5 | Evidence Strength of Pharmaceutical Industry-Funded Clinical Trials in Metastatic NSCLC: A Comparison With Other Sources of Funding. Journal of Thoracic Oncology, 2020, 15, 1170-1176. | 1.1 | 5 |
| 6 | Cost-effectiveness analysis of abiraterone, docetaxel or placebo plus androgen deprivation therapy for hormone-sensitive advanced prostate cancer. Einstein (Sao Paulo, Brazil), 2019, 17, eGS4414. | 0.7 | 15 |
| 7 | Potential life years not saved due to lack of access to anti-EGFR tyrosine kinase inhibitors for lung cancer treatment in the Brazilian public healthcare system: Budget impact and strategies to improve access. A pharmacoeconomic study. Sao Paulo Medical Journal, 2019, 137, 505-511. | 0.9 | 1 |
| 8 | Treatment of Metastatic Renal Cell Carcinoma: Latest Evidence and Ongoing Challenges. Clinical Medicine Insights Urology, 2018, 11, 117956111876575. | 0.4 | 1 |
| 9 | Comparative effectiveness of immune-checkpoint inhibitors for previously treated advanced non-small cell lung cancer – A systematic review and network meta-analysis of 3024 participants. Lung Cancer, 2018, 115, 84-88. | 2.0 | 39 |
| 10 | Addition of abiraterone, docetaxel, bisphosphonate, celecoxib or combinations to androgen-deprivation therapy (ADT) for metastatic hormone-sensitive prostate cancer (mHSPC): a network meta-analysis. Prostate Cancer and Prostatic Diseases, 2018, 21, 516-523. | 3.9 | 25 |
| 11 | A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors. Drugs in Context, 2018, 7, 1-6. | 2.2 | 8 |
| 12 | OA17.01 Estimate of Economic Impact of Immune Checkpoint Inhibitors for NSCLC Relative to PD-L1 Expression in the US. Journal of Thoracic Oncology, 2017, 12, S308. | 1.1 | 1 |
| 13 | MA14.11 An Estimate of the Economic Impact of Immunotherapy Relative to PD-L1 Expression in Brazil - An Update with Brazilian Costs. Journal of Thoracic Oncology, 2017, 12, S427. | 1.1 | 1 |
| 14 | PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data. Immunotherapy, 2017, 9, 499-506. | 2.0 | 162 |
| 15 | The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC. Annals of Oncology, 2017, 28, 2256-2263. | 1.2 | 72 |
| 16 | P3.02b-081 Comparative Outcome Assessment of EGFR TKIs for the Treatment of Advanced Non-Small-Cell Lung Cancer: A Network Meta-Analysis. Journal of Thoracic Oncology, 2017, 12, S1239-S1240. | 1.1 | 0 |
| 17 | OA23.01 Anti-EGFR Monoclonal Antibodies plus Chemotherapy in the First-Line Treatment of Advanced NSCLC: A Meta-Analysis. Journal of Thoracic Oncology, 2017, 12, S333-S334. | 1.1 | 0 |
| 18 | Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets. ESMO Open, 2017, 2, e000200. | 4.5 | 31 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Genetic Polymorphisms of Vitamin D Metabolism Genes and Serum Level of Vitamin D in Colorectal Cancer. <i>International Journal of Biological Markers</i> , 2017, 32, 441-446. | 1.8 | 9 |
| 20 | P2.03-006 How Many Years of Life Have We Lost in Brazil Due to the Lack of Access to Anti-EGFR TKIs in the National Public Health System?. <i>Journal of Thoracic Oncology</i> , 2017, 12, S2129. | 1.1 | 4 |
| 21 | P2.07-055 Indirect Comparison between Immune-Checkpoint Inhibitors for 2nd Line Non-Small Cell Lung Cancer â a Network Meta-Analysis. <i>Journal of Thoracic Oncology</i> , 2017, 12, S2150. | 1.1 | 1 |
| 22 | P3.03-019 Activity of PARP Inhibitor in NSCLC with Germline and Somatic Mutation and in Silico Chemotherapy Lethality. <i>Journal of Thoracic Oncology</i> , 2017, 12, S2280. | 1.1 | 0 |
| 23 | P1.11-001 Economic Impact of Immune Checkpoint Inhibitor Therapy in Brazil and Strategies to Improve Access. <i>Journal of Thoracic Oncology</i> , 2017, 12, S2026. | 1.1 | 1 |
| 24 | P2.07-054 Cost-Effectiveness of Pembrolizumab as First-Line Therapy for Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2017, 12, S2149-S2150. | 1.1 | 1 |
| 25 | Cost effectiveness of chemohormonal therapy in patients with metastatic hormone-sensitive and non-metastatic high-risk prostate cancer. <i>Einstein (Sao Paulo, Brazil)</i> , 2017, 15, 349-354. | 0.7 | 11 |
| 26 | Temporary Dysarthria Induced by Irinotecan-Case Report of This Rare Adverse Event. <i>Journal of Pharmacy and Pharmacology</i> , 2017, 5, . | 0.0 | 0 |
| 27 | Disparities in cancer epidemiology and care delivery among Brazilian indigenous populations. <i>Einstein (Sao Paulo, Brazil)</i> , 2016, 14, 330-337. | 0.7 | 7 |
| 28 | Brazilian data of renal cell carcinoma in a public university hospital. <i>International Braz J Urol: Official Journal of the Brazilian Society of Urology</i> , 2016, 42, 29-36. | 1.5 | 2 |
| 29 | HER2 EXPRESSION AS A PROGNOSTIC FACTOR IN METASTATIC GASTRIC CANCER. <i>Arquivos De Gastroenterologia</i> , 2016, 53, 62-67. | 0.8 | 7 |
| 30 | P2.45: An Estimate of the Economic Impact of Treatment of NSCLC With Immunotherapy Relative to PD-L1 Expression in Brazil. <i>Journal of Thoracic Oncology</i> , 2016, 11, S246. | 1.1 | 1 |
| 31 | P2.44: An Update of a Pooled Analysis of Nivolumab for the Treatment of Advanced NSCLC and the Role of PD-L1 as a BIOMARKER. <i>Journal of Thoracic Oncology</i> , 2016, 11, S245. | 1.1 | 0 |
| 32 | PD1.02 (also presented as P2.47): The Role of PD-L1 Expression as a Predictive Biomarker in Advanced NSCLC: An Update of a Network Meta-Analysis. <i>Journal of Thoracic Oncology</i> , 2016, 11, S171-S172. | 1.1 | 0 |
| 33 | O.03: Cost Effectiveness of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer Relative to PD-L1 Expression. <i>Journal of Thoracic Oncology</i> , 2016, 11, S169-S170. | 1.1 | 7 |
| 34 | A pooled analysis of nivolumab for the treatment of advanced non-small-cell lung cancer and the role of PD-L1 as a predictive biomarker. <i>Immunotherapy</i> , 2016, 8, 1011-1019. | 2.0 | 34 |
| 35 | Definitive chemoradiotherapy for squamous head and neck cancer: cisplatin versus carboplatin? A meta-analysis. <i>Future Oncology</i> , 2016, 12, 2755-2764. | 2.4 | 7 |
| 36 | Cost effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression. <i>Lung Cancer Management</i> , 2016, 5, 119-122. | 1.5 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Cost effectiveness and estimate of economical impact of immune checkpoint inhibitors for NSCLC relative to PD-L1 expression. <i>Annals of Oncology</i> , 2016, 27, vi423. | 1.2 | 0 |
| 38 | The role of PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: a network meta-analysis. <i>Immunotherapy</i> , 2016, 8, 479-488. | 2.0 | 136 |
| 39 | Current advances in targeted therapies for metastatic gastric cancer: improving patient care. <i>Future Oncology</i> , 2016, 12, 839-854. | 2.4 | 3 |
| 40 | Cost effectiveness of immune checkpoint inhibitors in NSCLC according to PD-L1 expression.. <i>Journal of Clinical Oncology</i> , 2016, 34, 9033-9033. | 1.6 | 1 |
| 41 | EGFR and EML4-ALK Updated Therapies in Non-Small Cell Lung Cancer. <i>Recent Patents on Anti-Cancer Drug Discovery</i> , 2016, 11, 393-400. | 1.6 | 8 |
| 42 | 2826 Definitive chemoradiotherapy for loco-regionally advanced squamous cell head and neck cancer: Is cisplatin more effective than carboplatin? - a systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2015, 51, S566-S567. | 2.8 | 0 |
| 43 | 3122 The role of PD-L1 expression as a predictive biomarker in advanced non-small cell lung cancer: A network meta-analysis. <i>European Journal of Cancer</i> , 2015, 51, S644. | 2.8 | 1 |
| 44 | 1027 Disparities in cancer epidemiology and care delivery among Brazilian indigenous populations. <i>European Journal of Cancer</i> , 2015, 51, S154. | 2.8 | 0 |
| 45 | HUMAN DNA QUANTIFICATION IN THE STOOLS OF PATIENTS WITH COLORECTAL CANCER. <i>Arquivos De Gastroenterologia</i> , 2015, 52, 293-298. | 0.8 | 11 |
| 46 | 3080 Polled analysis of nivolumab for the treatment of advanced non-small cell lung cancer and the role of PD-L1 as a biomarker. <i>European Journal of Cancer</i> , 2015, 51, S624. | 2.8 | 0 |
| 47 | Treating operable patients with gastric cancer: Macdonald's protocol versus adjuvant chemotherapy. <i>Future Oncology</i> , 2015, 11, 2247-2249. | 2.4 | 2 |
| 48 | MMR deficiency may lead to a high immunogenicity and then an improvement in anti-PD-1 efficacy for metastatic colorectal cancer. <i>Immunotherapy</i> , 2015, 7, 1133-1134. | 2.0 | 9 |
| 49 | Individualized Chemotherapy for Metastatic Gastric Cancer: Retrospective Data from a University Hospital in Brazil. <i>Asian Pacific Journal of Cancer Prevention</i> , 2015, 16, 5289-5296. | 1.2 | 0 |
| 50 | Atezolizumab for previous treated advanced non-small-cell lung cancer: should it be worthy for the clinical practice?. <i>AME Medical Journal</i> , 0, 2, 34-34. | 0.4 | 0 |